-
Product Insights
NewLikelihood of Approval Analysis for Rhabdoviridae Infections
Overview How likely is it that the drugs in Rhabdoviridae Infections will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rhabdoviridae Infections Overview The family Rhabdoviridae are negatively stranded RNA viruses consisting...
-
Product Insights
NewLikelihood of Approval Analysis for Picornaviridae Infections
Overview How likely is it that the drugs in Picornaviridae Infections will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Picornaviridae Infections Overview The family PICORNAVIRIDAE comprises five genera, namely, enteroviruses, rhinoviruses,...
-
Product Insights
NewLikelihood of Approval Analysis for Enterobacteriaceae Infections
Overview How likely is it that the drugs in Enterobacteriaceae Infections will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Enterobacteriaceae Infections Overview Enterobacteriaceae are a large family of Gram-negative bacteria that...
-
Product Insights
NewLikelihood of Approval Analysis for Neisseriaceae Infections
Overview How likely is it that the drugs in Neisseriaceae Infections will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Neisseriaceae Infections Overview The Neisseriaceae family encompasses a group of bacteria, including...
-
Product Insights
NewLikelihood of Approval Analysis for Filoviridae Infections
Overview How likely is it that the drugs in Filoviridae Infections will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Filoviridae Infections Overview Filovirideae infections are caused by viruses in the family...
-
Product Insights
NewLikelihood of Approval Analysis for Hepadnaviridae Infections
Overview How likely is it that the drugs in Hepadnaviridae Infections will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Hepadnaviridae Infections Overview Hepadnaviridae infections are caused by a family of viruses...
-
Product Insights
NewLikelihood of Approval Analysis for Paramyxoviridae Infections
Overview How likely is it that the drugs in Paramyxoviridae Infections will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Paramyxoviridae Infections Overview The Paramyxoviridae family belongs to the order Mononegavirales, the...
-
Sector Analysis
Bacterial Vaginosis (BV) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Bacterial Vaginosis (BV) Marketed and Pipeline Drugs Report Overview Bacterial Vaginosis is the most commonly occurring vaginal infection in women of reproductive age. It occurs when the healthy vaginal flora is dominated by BV-associated bacteria (BVAB). The most common BVAB includes Gardnerella vaginalis, Atopobium vaginae, Megasphaera spp., Prevotella spp., and Sneathia spp. BVAB is caused by almost 35 unique bacterial species: a few of them are less frequently detected, including species such as Peptostreptococcus spp., Aerococcus, Anaerococcus, Gemella, and Veillonella...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Psilocybin in Substance (Drug) Abuse
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Psilocybin in Substance (Drug) AbuseDrug Details:Psilocybin is under development for the treatment of substance abuse disorder,...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – psilocybin
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry psilocybin Drug Details Psilocybin is under development for the treatment of substance abuse disorder,...